VANCOUVER, Oct. 4th, 2017 - Segra International Corp. is pleased to announce that its application to Health Canada to produce medical cannabis through its wholly-owned subsidiary Segra Biogenesis Corp. has progressed to the Advanced Review stage. In this stage, applications are thoroughly reviewed by Health Canada to validate the information provided. Upon completion of the review, the Company is expected to move to Pre-License Inspection (inspection of finished facility), followed by Final Licensing. Segra has cleared its Vancouver Island property and completed a geotechnical assessment in order to commence facility construction.
The proposed facility will include a dedicated cannabis tissue culture (TC) nursery, enabling the industrial-scale production of pathogen-free, genetically identical, stable and robust plantlets. These plantlets will be sold to licensed producers in Canada and worldwide. Segra's TC specialist has a proven track record in plant TC, including cannabis, as well as extensive experience in designing and managing large industrial-scale nursery facilities capable of producing millions of plantlets annually.
"Segra plans to be a worldwide leader in cannabis tissue culture, starting with industrial-scale nurseries in both the Canadian and California markets. This is a thrilling time, and we look forward to continuing to execute on our strategic plans," said Todd McMurray, President/CEO.
Segra's Production Facility
Segra's ACMPR-licensed facility will be designed to produce both mature cannabis plants and immature TC plantlets under pharmaceutical conditions. Segra's approach to cultivation places heavy emphasis on clean, automated growing chambers. This minimizes bio-contamination by using cGMP/ISO-compliant facilities and processes to continually optimize the operational flow and ensure quality standards throughout production. With dry summers and mild winters, the Vancouver Island site provides an ideal low-cost location for both cultivation and TC nursery operations. The cultivation side of the facility will enable the Company to develop unique cannabis strains for sale to medical and recreational cultivators. Current expansion capability is well in excess of 200 acres, positioning Segra for future flexibility to increase production on a massive scale to meet market demand.
Segra is a biotechnology company specializing in cannabis micropropogation (also known as ‘tissue culture') and is focused on producing standardized cannabis TC plantlets on an industrial scale to meet market demand. The Company is currently developing cannabis TC nurseries for markets in Canada and California. Segra is an applicant to Health Canada to produce and distribute cannabis TC plantlets under the ACMPR. Segra leverages expertise in plant tissue culture, agronomy, botany, biochemistry, molecular genetics and production under strict regulatory environments to ensure high-quality products.
The Company will be releasing further plans about TC developments in California in the very near future.
On behalf of the Board of Directors,
Todd McMurray, President/CEO
SEGRA INTERNATIONAL CORP.
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
For further information, contact